Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The REMS Filibuster: FDA Wants Ability To End Post-Approval Talks, Make Final Decision

Executive Summary

FDA wants a bigger stick for product-specific Risk Evaluation and Mitigation Strategy negotiations, if for no other reason than to end the talks and make the final decision.

You may also be interested in...



Burr Warns User Fee Renewal Could Be Difficult Without Performance Measure Improvements

Senator tells FDA Commissioner Hamburg that time to market is important metric during hearing dominated by questions about medical device review.

Cephalon’s Fentanyl Drugs Join Class-Wide REMS; Shared System Still To Come

Cephalon’s Actiq and Fentora will undergo increased distribution restrictions after joining FDA’s class-wide REMS for transmucosal fentanyl drugs, but a shared system, one of the main tenets of the risk management plan, is still under development.

Cephalon’s Fentanyl Drugs Join Class-Wide REMS; Shared System Still To Come

Cephalon’s Actiq and Fentora will undergo increased distribution restrictions after joining FDA’s class-wide REMS for transmucosal fentanyl drugs, but a shared system, one of the main tenets of the risk management plan, is still under development.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel